Charlie Scott

891 total citations · 1 hit paper
23 papers, 462 citations indexed

About

Charlie Scott is a scholar working on Endocrinology, Diabetes and Metabolism, Cardiology and Cardiovascular Medicine and Molecular Biology. According to data from OpenAlex, Charlie Scott has authored 23 papers receiving a total of 462 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Endocrinology, Diabetes and Metabolism, 9 papers in Cardiology and Cardiovascular Medicine and 5 papers in Molecular Biology. Recurrent topics in Charlie Scott's work include Hormonal Regulation and Hypertension (14 papers), Diabetes Treatment and Management (11 papers) and Diet and metabolism studies (5 papers). Charlie Scott is often cited by papers focused on Hormonal Regulation and Hypertension (14 papers), Diabetes Treatment and Management (11 papers) and Diet and metabolism studies (5 papers). Charlie Scott collaborates with scholars based in United States, Germany and Denmark. Charlie Scott's co-authors include Peter Rossing, George L. Bakris, Luís M. Ruilope, Stefan D. Anker, Bertram Pitt, Gerasimos Filippatos, Amer Joseph, Rajiv Agarwal, Janet B. McGill and Hiddo J.L. Heerspink and has published in prestigious journals such as New England Journal of Medicine, Journal of the American College of Cardiology and Diabetes Care.

In The Last Decade

Charlie Scott

16 papers receiving 458 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes

2025 44 citations Rajiv Agarwal, Jennifer B. Green et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Charlie Scott

Since Specialization

Citations

This map shows the geographic impact of Charlie Scott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charlie Scott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charlie Scott more than expected).

Fields of papers citing papers by Charlie Scott

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charlie Scott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charlie Scott. The network helps show where Charlie Scott may publish in the future.

Co-authorship network of co-authors of Charlie Scott

This figure shows the co-authorship network connecting the top 25 collaborators of Charlie Scott. A scholar is included among the top collaborators of Charlie Scott based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charlie Scott. Charlie Scott is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Impact of Simultaneous Initiation of Finerenone and Empagliflozin on Urinary Albumin-to-Creatinine Ratio in Asia 2025 ·Clinical Journal of the American Society of Nephrology ·Rajiv Agarwal, Jennifer B. Green, Hiddo J.L. Heerspink, Johannes F.E. Mann, Janet B. McGill, Amy K. Mottl, Takeshi Osonoi, (unknown), Peter Rossing, Julio Rosenstock, Muthiah Vaduganathan, Li Li, (unknown), Charlie Scott, (unknown), Satoshi Yamashita, Masaomi Nangaku	0
2	Efficacy and safety of finerenone in patients with an acute change in estimated glomerular filtration rate in the prespecified FIDELITY pool analysis 2025 ·Kidney International ·Sankar D. Navaneethan, Stefan D. Anker, Gerasimos Filippatos, Bertram Pitt, Peter Rossing, Luís M. Ruilope, Phyllis August, Meike Brinker, Andrea Lage, Luke Roberts, Charlie Scott, Pantelis Sarafidis	7
3	Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both 2025 ·Journal of the American College of Cardiology ·Rajiv Agarwal, Jennifer B. Green, (unknown), Janet B. McGill, Amy K. Mottl, Masaomi Nangaku, Julio Rosenstock, (unknown), Muthiah Vaduganathan, Carolina Solis‐Herrera, Charlie Scott, Li Li, (unknown), (unknown), Johannes F.E. Mann	0
4	Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both 2025 ·Journal of the American Society of Nephrology ·Amy K. Mottl, Charlie Scott, Jennifer B. Green, Hiddo J.L. Heerspink, Johannes F.E. Mann, Janet B. McGill, Masaomi Nangaku, Julio Rosenstock, Peter Rossing, Li Li, (unknown), Muthiah Vaduganathan, Rajiv Agarwal, (unknown)	0
5	Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes breakdown → 2025 ·New England Journal of Medicine ·Rajiv Agarwal, Jennifer B. Green, Hiddo J.L. Heerspink, Johannes F.E. Mann, Janet B. McGill, Amy K. Mottl, Julio Rosenstock, Peter Rossing, Muthiah Vaduganathan, Meike Brinker, Robert Edfors, (unknown), Markus F. Scheerer, Charlie Scott, Masaomi Nangaku	44
6	Finerenone and Clinical Outcomes in CKD and Type 2 Diabetes by Frailty Index 2025 ·Clinical Journal of the American Society of Nephrology ·Peter Rossing, Andreas L. Birkenfeld, Paola Fioretto, Janet B. McGill, Stefan D. Anker, Bertram Pitt, Katja Rohwedder, Andrea Scalise, Charlie Scott, Gerasimos Filippatos, (unknown)	0
7	Outcomes With Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Baseline Insulin Resistance 2023 ·Diabetes Care ·Thomas Ebert, Stefan D. Anker, Luís M. Ruilope, Paola Fioretto, Vivian Fonseca, Guillermo E. Umpierrez, Andreas L. Birkenfeld, Robert Lawatscheck, Charlie Scott, Katja Rohwedder, Peter Rossing, (unknown)	19
8	Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial 2023 ·Diabetes Research and Clinical Practice ·Hiddo J.L. Heerspink, Andreas L. Birkenfeld, David Z.I. Cherney, Helen M. Colhoun, Linong Ji, Chantal Mathieu, Per‐Henrik Groop, Richard E. Pratley, Sylvia E. Rosas, Peter Rossing, Jay S. Skyler, Katherine R. Tuttle, Robert Lawatscheck, Charlie Scott, Robert Edfors, Markus F. Scheerer, Peter Kolkhof, Janet B. McGill	27
9	Finerenone in Hispanic Patients With CKD and Type 2 Diabetes: A Post Hoc FIDELITY Analysis 2023 ·Kidney Medicine ·Sylvia E. Rosas, Luís M. Ruilope, Stefan D. Anker, Bertram Pitt, Peter Rossing, (unknown), Ricardo Correa‐Rotter, Fernando González, (unknown), Pablo E. Pérgola, Guillermo E. Umpierrez, Andrea Scalise, Charlie Scott, Robert Lawatscheck, Amer Joseph, George L. Bakris	1
10	Cardiorenal Outcomes with Finerenone in Asian Patients with Chronic Kidney Disease and Type 2 Diabetes: A FIDELIO-DKD post hoc Analysis 2023 ·American Journal of Nephrology ·Daisuke Koya, Stefan D. Anker, Luís M. Ruilope, Peter Rossing, Zhihong Liu, Byung‐Wan Lee, Chien‐Te Lee, Charlie Scott, Peter Kolkhof, Robert Lawatscheck, Lili Wang, Amer Joseph, Bertram Pitt, (unknown)	10
11	Risk of chronic kidney disease in patients with acute kidney injury following a major surgery: a US claims database analysis 2023 ·Clinical Kidney Journal ·Christoph Ohlmeier, Johannes Schuchhardt, Chris Bauer, Meike Brinker, Sheldon X. Kong, Charlie Scott, (unknown)	6
12	Effects of finerenone in people with chronic kidney disease and type 2 diabetes are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at baseline 2023 ·Diabetes Obesity and Metabolism ·Janet B. McGill, Rajiv Agarwal, Stefan D. Anker, George L. Bakris, Gerasimos Filippatos, Bertram Pitt, Luís M. Ruilope, Andreas L. Birkenfeld, Maria Luiza Caramori, Meike Brinker, Amer Joseph, Andrea Lage, Robert Lawatscheck, Charlie Scott, Peter Rossing, (unknown)	9
13	Efficacy of finerenone in patients with type 2 diabetes, chronic kidney disease and altered markers of liver steatosis and fibrosis: A FIDELITY subgroup analysis 2023 ·Diabetes Obesity and Metabolism ·Nikolaos Perakakis, Stefan R. Bornstein, Andreas L. Birkenfeld, Andreas Linkermann, Münevver Demir, Stefan D. Anker, Gerasimos Filippatos, Bertram Pitt, Peter Rossing, Luís M. Ruilope, Peter Kolkhof, Robert Lawatscheck, Charlie Scott, George L. Bakris, (unknown)	5
14	Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO‐DKD trial 2022 ·European Journal of Heart Failure ·Gerasimos Filippatos, Bertram Pitt, Rajiv Agarwal, Dimitrios Farmakis, Luís M. Ruilope, Peter Rossing, Johann Bauersachs, Robert J. Mentz, Peter Kolkhof, Charlie Scott, Amer Joseph, George L. Bakris, Stefan D. Anker, (unknown)	40
15	Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE) 2022 ·Nephrology Dialysis Transplantation ·Jennifer B. Green, Amy K. Mottl, George L. Bakris, Hiddo J.L. Heerspink, Johannes F.E. Mann, Janet B. McGill, Masaomi Nangaku, Peter Rossing, Charlie Scott, Alain Gay, Rajiv Agarwal	107
16	Association of Urine Albumin-to-Creatinine Ratio and Its Early Change with Cardiorenal Outcomes in FIDELIO-DKD: A Mediation Analysis 2021 ·Journal of the American Society of Nephrology ·Rajiv Agarwal, Stefan D. Anker, Bertram Pitt, Luís M. Ruilope, Peter Rossing, Meike Brinker, Amer Joseph, Robert Lawatscheck, Charlie Scott, Gerasimos Filippatos, George L. Bakris	0
17	Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy 2021 ·Kidney International Reports ·Peter Rossing, Gerasimos Filippatos, Rajiv Agarwal, Stefan D. Anker, Bertram Pitt, Luís M. Ruilope, Juliana C.N. Chan, Adriaan Kooy, Kieran McCafferty, Guntram Schernthaner, Christoph Wanner, Amer Joseph, Markus F. Scheerer, Charlie Scott, George L. Bakris	101
18	14-LB: Finerenone in Patients with CKD and T2D by SGLT2i Treatment: An Analysis of the FIDELIO-DKD Study 2021 ·Diabetes ·Peter Rossing, Rajiv Agarwal, Stefan D. Anker, Gerasimos Filippatos, Bertram Pitt, Luís M. Ruilope, Juliana C.N. Chan, Adriaan Kooy, Kieran McCafferty, Guntram Schernthaner, Christoph Wanner, Amer Joseph, Markus F. Scheerer, Charlie Scott, George L. Bakris	2
19	Importance of trial design when investigating cardiorenal outcomes in patients with CKD and T2D: Focus on CREDENCE and FIDELIO-DKD 2021 ·American Heart Journal ·Rajiv Agarwal, Stefan D. Anker, (unknown), Bertram Pitt, Peter Rossing, Luís M. Ruilope, John Boletis, Robert Toto, Guillermo E. Umpierrez, Christoph Wanner, Takashi Wada, Charlie Scott, Amer Joseph, Ike Ogbaa, (unknown)	1
20	405-P: Efficacy and Safety of Finerenone in Patients with CKD and T2D by Baseline Insulin Treatment 2021 ·Diabetes ·Peter Rossing, Rajiv Agarwal, Stefan D. Anker, (unknown), Bertram Pitt, Luís M. Ruilope, Richard J. MacIsaac, Julio Wainstein, Amer Joseph, Lothar Roessig, Charlie Scott, George L. Bakris	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact